Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think a rough ballpark figure is that we get 5% of the company and upon listing it goes from 50 million to 150 million within a few weeks.
That would give us approx 2.5x returns on pre suspension prices.
The 5% is maybe a little bit blue-sky thinking. But you have to be able to attribute some significant value to BOU being able to list Accustem within days/weeks of the EGM (rather that a 6 month IPO), with limited costs, with some cash in the coffers of Bould, and with Syms having some extremely useful connections and experience in the metastasis/oncology field.
This will be a fantastic earner for all of us. Should you choose to ride it out until Accustem is bought out then I wouldn't expect 10x returns from pre-suspension levels...
I just thought it could give us a very rough ball park figure, but yh there is so many variables, thanks for sharing your research, if it turns out not to be accustem i cant blame you for thinking it was
Hi asaynor.. Sorry I don't know what sort of equity spilt was involved when TILS rto'd into Alexander David Investments... And I don't think it has any relevance here.
The value in Accustem is very likely to be in the 3-6 months after listing (when a takeover will become more and more likely). Initial listing may well be in the 100-150 mil range.. And if BOU holders only get a few percent then we could be left feeling a little short changed.
But a large pharma is likely to come sniffing. And that's where the profit will be.
Hi jp, do you know what sort of deal shareholders at ‘david alexander investments’ got when tils rto’d? Just thought we may roughly get a similar deal if its StemPrintER
Hi folks. I'm on the fence with this one too. I agree that there are some links. Lots of coincidences. It does have some legs imo
@jace I did just that. After some research I took a small position in TILS sub £1 as the fundamentals look good there. May loose or gain on neither, one or both. That's the nature of investing.
GL To all what ever your view.
ATB LB
Hmm that’s right with tils shares. Anyway for around 2 weeks we will know if is them. I will repeat it again 0.5p per share as a starter is absolutely minimum after this nightmare. If we will get great co. I’m happy to hold longer.
Certainly wouldn't be happy either.
A given broker has a blank cheque to use authority to issue shares at any price they see fit.
The value then is where the market prices whatever comes to us on re-list.
If it is this (I don't think so yet) then could have just bought tils instead and not wasted my time here...
JPP
Interesting reading and I certainly hope that you are proved to be correct, seem to have been holding the BOU shares for a very long time now, been in since the late PSL days when the shares were changing hands for a pittance
Chris
We will find out in the next two weeks I reckon. They mentioned shortly after meeting which is next week hmm. Looks like JPP could be right. If so hats off. Right so for me to be under 0.1 as JPP mentioned will be massive disappointment. What is a point to wait in stress and with funds locked so long over suspension AND even delisting from market etc. Add to this ISA tax wasted. If this deal is good and stemprinter have massive, extraordinary potential anyone could jump in on re-admission. Main thing in RTO is a high premium. What for all this if we will start from low level?!
Mtfb chat.. sorry for the typo..
This is what I found on the MTFM Chat..
From TILS LSE - Considering Tiziana themselves were listen in 2013 via a cash shell (Alexander David Investments plc) then I think a listing via a RTO is likely. I do however think that it will be Bould Opportunities that are used as the vehicle to list Accustem...
The share a similar registered office (Cheapside London)
Bould CEO Syms has previous experience with spin outs
Syms completed a PhD in Cancer Research at Cardiff University.. Tiziana was founded originally by a group of 3 scientists at that same University... Cerrone was part funder of the original study..
Syms was a speaker at BioMotif in Cardiff in 2013 (about the same time Tiziana was founded)
Fair play JPP8788, you certainly have done some background work here and everything you have said over recent weeks makes sense, could be coincidence, could be more to it and you are right, guess we do not have too much longer to wait and see.
Certainly would be a very good opportunity for Bould share holders who all deserve something here (myself included), we have been patient and supportive over the last year or more, many taken up the OO (myself included), so would love to see this eventually work out.
I do hope you are right, best of luck!
A little more of my own research here to keep you all amused...
If you go back around 7 years, Tiziana Life Sciences was formed originally by a team of three - Brancale, Clarkson and Westwell... Cerrone himself part funded the research into metastasis specifically.
This was done a few years after GC lost his wife to breast cancer.. And has been interviewed many times saying that he wants to make a difference to other victims lifespan.
Cerrone then listed TILS on AIM around a year later, RTOing into a cash shell previously known as "Alexander David Investments plc", and subsequently bought out the three other directors a few years afterwards.
So why is this all important? Well.. I guess the fact TILS were formed from a cash shell is of significant interest.. But actually... Let's look back to the start... Cardiff University.. Where it all began..
Is there a connection between the city of Cardiff (and the university itself) and our CEO, Allan Syms? I'll leave the answer to find out for yourselves.. But the fact that Syms completed a PhD in Cancer Research at Cardiff University.. And the fact that Syms other venture, MyPinPad, is also listed in Cardiff... There are other links too... You just have to find them.
Join the dots people...